Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67
Authors:
- 3 February 2011
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 18 (2) , 98-102
Abstract
The immunohistochemical (IHC) biomarkers of breast cancer, especially hormone receptors and HER2, are very important because the pharmacological therapeutic strategy is generally decided by biomarker expression patterns. Biomarkers are examined on pre-chemotherapeutic biopsy materials from patients in whom neoadjuvant chemotherapy is planned. Statistically significant changes between pre- and post-chemotherapeutic markers have been reported; however, the alterations in biomarkers are poorly understood. Fluctuation of the Ki-67 labeling index (LI) between pre- and post-neoadjuvant therapy is associated with chemotherapeutic effects and with the prognosis of patients. It has been shown that IHC evaluation of Ki-67 LI is useful as a predictive and a prognostic factor. There are issues to be considered surrounding the use of the IHC Ki-67 LI in routine practice, including the standardization of staining procedures and a cutoff point for Ki-67 LI detection. The current understanding of IHC evaluation of biomarkers for breast cancer under neoadjuvant chemotherapy is reviewed based on the literature.Keywords
This publication has 23 references indexed in Scilit:
- Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant settingThe Breast, 2009
- Predictive markers of response to neoadjuvant chemotherapy in breast cancerSurgical Oncology, 2008
- The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast CarcinomaThe Breast Journal, 2008
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized TrialsJNCI: Journal of the National Cancer Institute, 2008
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007Annals of Oncology, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive SignaturesZentralblatt Fur Gynakologie, 2006
- Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.Endocrine-Related Cancer, 2003
- Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?Journal of Surgical Oncology, 1994